TrialJournal of hematology & oncology2014

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.

Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.